Xencor Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xencor Inc (XNCR)
Xencor Inc stock price live, this page displays NASDAQ XNCR stock exchange data. View the XNCR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xencor Inc real time stock price chart below.
What Is the Xencor Inc Stock Price Today?
The Xencor Inc stock price today is 12.77.
What Is the Stock Symbol for Xencor Inc?
The stock symbol for Xencor Inc is "XNCR."
What Stock Exchange Does Xencor Inc Trade On?
Xencor Inc is listed and trades on the NASDAQ stock exchange.
Is Xencor Inc a Good Stock to Buy?
Determining whether Xencor Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XNCR quote. (ISIN: US98401F1057)
What Is the Xencor Inc Stock Price Today?
The Xencor Inc stock price today is 12.77.
What Is the Stock Symbol for Xencor Inc?
The stock symbol for Xencor Inc is "XNCR."
What Stock Exchange Does Xencor Inc Trade On?
Xencor Inc is listed and trades on the NASDAQ stock exchange.
Is Xencor Inc a Good Stock to Buy?
Determining whether Xencor Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XNCR quote. (ISIN: US98401F1057)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.67
13.57
52 wk Range
6.92
18.69
XNCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.6713.57
52 wk Range
6.9218.69
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XNCR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
28.83
Upside
+125.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
- Form S-3ASR Xencor Inc For: 25 February
- Investing.com
- Xencor Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form S-3ASR Xencor Inc For: 25 February
- Investing.com
- Form 13G XENCOR INC For: 9 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Xencor Inc Company Profile
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Xencor Inc SWOT Analysis
Pipeline Progress | Explore Xencor's advancing clinical trials, including XmAb942 for ulcerative colitis and XmAb819 for kidney cancer, showcasing potential in diverse therapeutic areas |
Financial Fortitude | Delve into Xencor's robust $693.5M cash reserve, funding operations through 2028 despite current losses, and its impact on R&D flexibility and partnership leverage |
Market Dynamics | Learn how Xencor navigates the competitive TL1A antibody space, balancing innovation against established players and emerging threats in biotech |
Valuation Insights | Discover analyst perspectives on Xencor, with price targets ranging from $6 to $32, reflecting varied views on the company's pipeline potential and market position |
Xencor Inc Earnings Call Summary for Q4/2023
- Vudalimab shows promising results in prostate cancer treatment, with confirmed partial response and PSA90 for over 22 weeks
- Xencor reducing investment in cytokine drugs, focusing on T-cell engagers for solid tumors; plans to select next IND candidate later this year
- Company strengthening balance sheet through monetization of Ultomiris and Monjuvi royalties
- Safety profile of vudalimab well-managed, with few treatment discontinuations; comparable to other checkpoint inhibitors
- Xencor aims to enroll ~30 patients per cohort for go/no-go decision on vudalimab efficacy; early data encouraging but awaiting further confirmation
Last Updated: 2024-02-28, 11:14 a/m
Read Full TranscriptCompare XNCR to Peers and Sector
Metrics to compare | XNCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXNCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.2x | −0.8x | −0.6x | |
PEG Ratio | −0.17 | −0.10 | 0.00 | |
Price/Book | 1.5x | 2.6x | 2.6x | |
Price / LTM Sales | 7.5x | 7.9x | 3.3x | |
Upside (Analyst Target) | 111.4% | 44.2% | 44.8% | |
Fair Value Upside | Unlock | 21.3% | 5.5% | Unlock |
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 28.83
(+125.79% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
-0.09 / -0.6014
Revenue / Forecast
28.24M / 29.99M
People Also Watch
FAQ
What Is the Xencor Inc (XNCR) Stock Price Today?
The Xencor Inc stock price today is 12.77 USD.
What Stock Exchange Does Xencor Inc Trade On?
Xencor Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Xencor Inc?
The stock symbol for Xencor Inc is "XNCR."
What Is the Xencor Inc Market Cap?
As of today, Xencor Inc market cap is 936.53M USD.
What Is Xencor Inc's Earnings Per Share (TTM)?
The Xencor Inc EPS (TTM) is -1.24.
When Is the Next Xencor Inc Earnings Date?
Xencor Inc will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is XNCR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Xencor Inc Stock Split?
Xencor Inc has split 0 times.
How Many Employees Does Xencor Inc Have?
Xencor Inc has 250 employees.
What is the current trading status of Xencor Inc (XNCR)?
As of Feb 28, 2026, Xencor Inc (XNCR) is trading at a price of 12.77 USD, with a previous close of 13.55 USD. The stock has fluctuated within a day range of 12.67 USD to 13.57 USD, while its 52-week range spans from 6.92 USD to 18.69 USD.
What Is Xencor Inc (XNCR) Price Target According to Analysts?
The average 12-month price target for Xencor Inc is 28.83 USD, with a high estimate of 43 USD and a low estimate of 18 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +125.79% Upside potential.
What Is the XNCR Premarket Price?
XNCR's last pre-market stock price is 13.80 USD. The pre-market share volume is 1,320.00, and the stock has decreased by 0.25, or 1.85%.
What Is the XNCR After Hours Price?
XNCR's last after hours stock price is 12.94 USD, the stock has decreased by 0.17, or 1.33%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.